BioCentury
ARTICLE | Company News

3SBio deal

September 17, 2012 7:00 AM UTC

3SBio said it is evaluating a non-binding proposal from CEO and Chairman Jing Lou and CPEChina Fund L.P. to acquire the Chinese biotech for $15 per ADS in cash. The price values 3SBio at about $331.2 million, based on about 22.1 million ADSs outstanding at June 30, 2012. The price is a 23% premium to 3SBio's close of $11.59 on Sept. 11, before the offer was made public. 3SBio could not be reached for details on Lou's and CPEChina Fund's current ownership stakes. The fund could not be reached for comment. ...